个人中心 - 老虎社区

yong168

IP属地：未知

帖子 · 193帖子 · 193
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- yong168yong168
  ·2021-12-31
  [晕]
  昨夜今晨：美股尾盘跳水！中概股逆势大涨
  昨夜今晨：①美股尾盘跳水！道指跌0.25%止步六连阳；②周四美油收高0.3%，布油涨0.1%；③桥水创始人达利欧预计美联储明年可能加息4-5次；④欧洲央行管委诺特：结束购债后可能会在2023年初加息。
  昨夜今晨：美股尾盘跳水！中概股逆势大涨
  2,299 评论
  1
  分享
  举报
- yong168yong168
  ·2021-12-31
  [财迷] [鼓掌]
  非常抱歉，此主贴已删除
  2,800 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-31
  [开心] [强] [鼓掌]
  非常抱歉，此主贴已删除
  2,074 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [捂脸] [喷血]
  传特斯拉等新能源汽车保费涨超50%，车险公司回应：不实
  新能源汽车商业保险专属产品正式上线，在车主群体和舆论中引起了轩然大波。
  传特斯拉等新能源汽车保费涨超50%，车险公司回应：不实
  1,692 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [惊讶]
  非常抱歉，此主贴已删除
  1,868 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [强]
  非常抱歉，此主贴已删除
  2,753 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [汗颜]
  非常抱歉，此主贴已删除
  2,440 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [得意]
  The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
  Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinic
  The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
  2,001 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [冷漠]
  ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today
  The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:
  ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today
  1,681 评论
  点赞
  分享
  举报
- yong168yong168
  ·2021-12-30
  [笑哭]
  非常抱歉，此主贴已删除
  1,695 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3570966674623757","uuid":"3570966674623757","gmtCreate":1607875794423,"gmtModify":1607875794423,"name":"yong168","pinyin":"yong168","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":8,"tweetSize":193,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692838300,"gmtCreate":1640911567648,"gmtModify":1640911567726,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[晕]&nbsp;","listText":"[晕]&nbsp;","text":"[晕]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692838300","repostId":"1157350742","repostType":4,"repost":{"id":"1157350742","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640908753,"share":"https://www.laohu8.com/m/news/1157350742?lang=&edition=full","pubTime":"2021-12-31 07:59","market":"hk","language":"zh","title":"昨夜今晨：美股尾盘跳水！中概股逆势大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1157350742","media":"老虎资讯综合","summary":"昨夜今晨：①美股尾盘跳水！道指跌0.25%止步六连阳；②周四美油收高0.3%，布油涨0.1%；③桥水创始人达利欧预计美联储明年可能加息4-5次；④欧洲央行管委诺特：结束购债后可能会在2023年初加息。","content":"<html><head></head><body><blockquote>昨夜今晨：①美股尾盘跳水！道指跌0.25%止步六连阳；②周四美油收高0.3%，布油涨0.1%；③桥水创始人达利欧预计美联储明年可能加息4-5次；④欧洲央行管委诺特：结束购债后可能会在2023年初加息。</blockquote><p>海外市场</p><p>1、美股尾盘跳水！道指跌0.25%止步六连阳</p><p>美股三大指数高开低走，标普和纳指在周四交易时段的最后几分钟转跌，道琼斯指数也结束六连阳。截至收盘，道琼斯指数跌0.25%，标普500指数跌0.30%，纳斯达克指数跌0.16%。</p><p>美股大型科技股表现不尽人意。按市值排序，苹果跌0.66%，微软跌0.77%，谷歌A跌0.34%，亚马逊跌0.33%，特斯拉跌1.46%，英伟达跌1.38%，仅Meta涨0.41%。</p><p>通常情况下，美股会在一年的最后五个交易日和新年的前两个交易日上涨，这种现象被称为“圣诞行情”。低于平均水平的交易量，加上许多投资者在假期休市，可能导致交易波动扩大。一些公司还在年底调整投资组合。</p><p>2、热门中概股周四收盘大涨 高途涨超21%</p><p>热门中概股周四收盘大涨，高途、爱奇艺、哔哩哔哩等涨幅居前；纳斯达克金龙中国指数收涨9.40%，创2008年以来最大单日涨幅。</p><p>高途涨超21%，爱奇艺、汽车之家涨超13%，哔哩哔哩、唯品会、贝壳涨超12%，阿里巴巴、趣头条涨超9%，网易涨近9%。</p><p>新能源汽车股中，蔚来汽车涨超14%，小鹏汽车涨近10%，理想汽车涨超8%。</p><p>3、欧股主要指数上涨 德国DAX30收涨0.34%</p><p>德国DAX30指数周四收涨0.34%，英国富时100指数跌0.19%，法国CAC40指数涨0.16%，欧洲斯托克50指数涨0.50%。</p><p>4、周四美油收高0.6% 逼近每桶77美元</p><p>美国原油期货价格周四收高。市场对于奥密克戎变异毒株阻碍经济复苏的担忧情绪缓解、迹象表明原油库存下降，令油价得到支撑。</p><p>周四，纽约商品交易所2月交割的西德州中质原油期货价格上涨43美分，涨幅0.6%，收于每桶76.99美元。</p><p>伦敦洲际交易所2月交割的布伦特原油期货价格上涨9美分，涨幅0.1%，收于每桶79.32美元。至此布伦特原油期货已经连续四个交易日上涨。</p><p>5、周四黄金期货收高0.5%</p><p>尽管美元企稳、美股走高，黄金期货价格周四仍然收涨。</p><p>投资者认为奥密克戎变异毒株对经济增长的威胁较小，推动周四美元企稳、美股攀升推动道指与标普500指数再创盘中新高。</p><p>6、年末美国失业救济数据发布 黄金上涨美债下跌</p><p>美国上周首次申请失业救济人数意外下降，表明尽管爆发新一轮疫情，但劳动力需求仍然强劲。</p><p>美国劳工部周四的数据显示，在截至12月25日的一周，首次申领失业救济人数总计为198，000人，较前一周期的修正水平下降8，000人。接受调查的经济学家预估中值为206，000人。</p><p>国际宏观</p><p>1、<a href=\"https://laohu8.com/NW/2195497346\" target=\"_blank\">桥水创始人达利欧：美联储可能加息4-5次 明年这将是一个敏感问题</a></p><p>全球最大对冲基金桥水基金创始人瑞·达利欧在接受记者专访时表示，预计美联储明年将加息4-5次，直到对股市产生负面影响为止。</p><p>对于当前的通胀压力，达利欧指出，美国现在有两种通胀：一种是当对商品和服务的需求超过生产能力时出现的周期性通货膨胀，另一种是由货币和信贷超发造成的货币通胀。</p><p>对于第二种通胀，他警告，如果现金和债券持有人要大举抛售这些资产，央行将不得不以更快速度加息，或者通过印钞和购买金融资产来维持低利率，而这将加剧通货膨胀。这给美联储的政策制定增加了难度。</p><p>2、<a href=\"https://laohu8.com/NW/2195491270\" target=\"_blank\">美国CDC：无论接种疫苗与否，民众应避免邮轮旅行</a></p><p>美国疾病控制与预防中心（CDC）周四建议民众不要乘坐邮轮旅行，无论他们的疫苗接种情况如何，因奥密克戎变种席卷全球，近期新冠阳性病例大幅增加。</p><p>CDC将对邮轮的旅行警告提高到了最高级别。该机构目前正调查或观察数十艘爆发新冠疫情的邮轮。</p><p>CDC警告称，新冠病毒在船上近距离人与人之间很容易传播，即使接种了新冠疫苗和加强针，在邮轮上感染病毒的几率也非常高。</p><p>3、<a href=\"https://laohu8.com/NW/2195494014\" target=\"_blank\">美国取消航班再超千次，混乱的假日旅行季还在继续</a></p><p>由于冠状病毒病例激增导致人手严重不足，美国航空公司的航班取消数量还在增长，周四又有1，170个航班被取消。而预报中的暴风雪可能在新年假期进一步打乱人们的出行。</p><p>根据FlightAware.com，截至纽约时间周四下午2：27，捷蓝航空取消了175个航班，占其计划航班的17%。Allegiant取消了93个航班，占计划航班的18%。联合航空取消了197个，占计划的9%。在中午之前，当天取消的航班数量已经超过周三全天的1，084个。</p><p>此前，因冬季风暴加上人手不足，美国在圣诞节周末至本周初有数千航班取消。</p><p>4、美国上周首次申领失业救济人数意外下降 凸显劳动力需求仍强劲</p><p>美国上周首次申请失业救济人数意外下降，表明尽管爆发新一轮疫情，但劳动力需求仍然强劲。</p><p>美国劳工部周四的数据显示，在截至12月25日的一周，首次申领失业救济人数总计为198，000人，较前一周期的修正水平下降8，000人。接受彭博调查的经济学家预估中值为206，000人。</p><p>截至12月18日当周的持续申请失业救济人数下降至172万，为去年3月以来最低。</p><p>5、<a href=\"https://laohu8.com/NW/2195695494\" target=\"_blank\">全美公务员待遇“天花板”？美媒披露福奇每年退休金可得35万美元</a></p><p>报道称，已为美国政府效力55年的福奇连续两年成为“全美收入最高的公务员”：2019年的收入为41.7万美元，2020年涨到43.4万美元。他的薪资水平比美国总统、上将以及大约430万美国政府雇员都高。</p><p>根据美国联邦人事管理局的标准，福奇退休金的计算方法是其3年最高收入的平均值，再乘以80%。如果他在2021年和2022年获得的薪资与2020年持平，那么其退休金能达到34.7万美元。</p><p>另外，他的“超长工龄”能带来额外的政府年金补贴，数额至少是每年8344美元。</p><p>6、以色列正式批准开放第四剂新冠疫苗接种 限免疫力低下人群</p><p>当地时间12月30日晚间，以色列卫生部总干事纳赫曼·阿什（Nachman Ash）正式批准向该国免疫力低下人群开放第四剂新冠疫苗接种，但仍未批准向60岁以上人群以及医务工作者开放。</p><p>7、欧洲央行管委诺特：结束购债后可能会在2023年初加息</p><p>欧洲央行管委诺特称，欧洲央行接近实现2%的中期通胀目标，2022年通胀保持在2%上方的可能性很大，虽说不会远超2%。如果物价继续出人意料地上涨，央行可能会比现在计划的更快地解除刺激措施。政策利率可能在2023年初债券购买结束后上升。</p><p>8、欧洲央行管委维斯科：预计2022年平均通胀率为3%</p><p>欧洲央行管委维斯科称，预计2022年平均通胀率为3%，然后逐渐回落至略低于2%的水平；2023-24年的通胀预期预计将低于2%，面临下行和上行的风险。</p><p>公司新闻</p><p>1、<a href=\"https://laohu8.com/NW/2195911044\" target=\"_blank\">特斯拉在美国召回约47.5万辆汽车 接近其去年全球交付总量</a></p><p>由于技术缺陷可能增加事故风险，特斯拉召回美国约47.5万辆汽车，几乎相当于其去年全球总交付量。</p><p>特斯拉计划召回2017年至2020年间生产的所有Model 3车型，总数多达356，309辆。该公司告诉国家公路交通安全管理局(NHTSA)，后视摄像头的线束可能会因打开和关闭后备箱而受损，阻碍图像显示。</p><p>根据NHTSA周四在官网上发布的另一份声明，特斯拉还将召回2014年以来组装的多达119，009辆Model S汽车，因为前纵梁存在问题，可能导致引擎盖意外打开。该公司表示将免费解决这两个问题。</p><p>2、<a href=\"https://laohu8.com/NW/2195129491\" target=\"_blank\">缺芯危机中唯一的大赢家：特斯拉</a></p><p>全球汽车行业均受“缺芯”影响，然而特斯拉今年的产量预计将比去年多出大约80%。因为强大的自研芯片能力和垂直整合能力，特斯拉不惧“芯片荒”，成为行业最大赢家。</p><p>3、<a href=\"https://laohu8.com/NW/2195049505\" target=\"_blank\">2021年全球并购交易首次突破5万亿美元大关 高盛连续第五年力拔头筹</a></p><p>2021年全球并购交易创下纪录，高盛集团坐稳头把交椅。</p><p>根据彭博汇编的数据，根据所经手交易的美元总价值计算，高盛连续第五年蝉联合并与收购交易顾问榜首。</p><p>高盛占据首席之际，全球并购和相关交易规模首次超过了5万亿美元。数据显示，该行给价值超过1万亿美元的交易提供了咨询，市场占比超过24%。</p><p>4、<a href=\"https://laohu8.com/NW/2195496957\" target=\"_blank\">美国航空业面临疫情考验 捷蓝航空宣布将取消约1280架次航班</a></p><p>捷蓝航空表示，由于机组人员中感染奥密克戎毒株的病例大幅增加，该公司将1月13日之前的航班班次减少约1280次。</p><p>捷蓝航空发言人称，预计在未来一到两周内，该公司大多数机组人员所在的东北部地区的新冠肺炎病例数量将继续激增，这意味着，在新增病例数量下降之前，继续取消航班的可能性很高。</p><p>5、<a href=\"https://laohu8.com/NW/2195495066\" target=\"_blank\">三星否认收购不要紧 Canaccord Genuity预计百健下行空间有限</a></p><p>Canaccord Genuity分析师Sumant Kulkarni维持百健（BIIB.US）“买入”评级，目标价390美元。</p><p>此前，韩国媒体报道称，三星集团正在就收购百健进行谈判，并称估值约为420亿美元。随后，三星旗下三星生物表示这些是不真实的信息。</p><p>Kulkarni在一份报告中表示：“平心而论，这看起来确实像是一种断然否认。但是，我们缺乏相关语言背景，无法弄清韩语文件中具体被认定为不真实内容的细微差别。”</p><p>6、<a href=\"https://laohu8.com/NW/2195496771\" target=\"_blank\">员工抱怨亚马逊太冷酷：工伤后得不到赔偿，还不让休假</a></p><p>据报道，一些亚马逊员工日前抱怨，他们在工作中受伤后，很难获得赔偿和休假。</p><p>今年6月有分析称，亚马逊仓储员工在工作中的重伤率几乎是业内其他公司的两倍。该数据显示，2020年亚马逊仓储员工在每20万小时工作中，平均有5.9起“严重”受伤事件。</p><p>相比之下，整个仓储行业每20万小时平均发生“严重”受伤事件3.3起。作为亚马逊在零售行业最大的竞争对手之一，沃尔玛每20万小时发生2.5起“严重”受伤事件，不到亚马逊重伤率的一半。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昨夜今晨：美股尾盘跳水！中概股逆势大涨 </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昨夜今晨：美股尾盘跳水！中概股逆势大涨 \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-31 07:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><blockquote>昨夜今晨：①美股尾盘跳水！道指跌0.25%止步六连阳；②周四美油收高0.3%，布油涨0.1%；③桥水创始人达利欧预计美联储明年可能加息4-5次；④欧洲央行管委诺特：结束购债后可能会在2023年初加息。</blockquote><p>海外市场</p><p>1、美股尾盘跳水！道指跌0.25%止步六连阳</p><p>美股三大指数高开低走，标普和纳指在周四交易时段的最后几分钟转跌，道琼斯指数也结束六连阳。截至收盘，道琼斯指数跌0.25%，标普500指数跌0.30%，纳斯达克指数跌0.16%。</p><p>美股大型科技股表现不尽人意。按市值排序，苹果跌0.66%，微软跌0.77%，谷歌A跌0.34%，亚马逊跌0.33%，特斯拉跌1.46%，英伟达跌1.38%，仅Meta涨0.41%。</p><p>通常情况下，美股会在一年的最后五个交易日和新年的前两个交易日上涨，这种现象被称为“圣诞行情”。低于平均水平的交易量，加上许多投资者在假期休市，可能导致交易波动扩大。一些公司还在年底调整投资组合。</p><p>2、热门中概股周四收盘大涨 高途涨超21%</p><p>热门中概股周四收盘大涨，高途、爱奇艺、哔哩哔哩等涨幅居前；纳斯达克金龙中国指数收涨9.40%，创2008年以来最大单日涨幅。</p><p>高途涨超21%，爱奇艺、汽车之家涨超13%，哔哩哔哩、唯品会、贝壳涨超12%，阿里巴巴、趣头条涨超9%，网易涨近9%。</p><p>新能源汽车股中，蔚来汽车涨超14%，小鹏汽车涨近10%，理想汽车涨超8%。</p><p>3、欧股主要指数上涨 德国DAX30收涨0.34%</p><p>德国DAX30指数周四收涨0.34%，英国富时100指数跌0.19%，法国CAC40指数涨0.16%，欧洲斯托克50指数涨0.50%。</p><p>4、周四美油收高0.6% 逼近每桶77美元</p><p>美国原油期货价格周四收高。市场对于奥密克戎变异毒株阻碍经济复苏的担忧情绪缓解、迹象表明原油库存下降，令油价得到支撑。</p><p>周四，纽约商品交易所2月交割的西德州中质原油期货价格上涨43美分，涨幅0.6%，收于每桶76.99美元。</p><p>伦敦洲际交易所2月交割的布伦特原油期货价格上涨9美分，涨幅0.1%，收于每桶79.32美元。至此布伦特原油期货已经连续四个交易日上涨。</p><p>5、周四黄金期货收高0.5%</p><p>尽管美元企稳、美股走高，黄金期货价格周四仍然收涨。</p><p>投资者认为奥密克戎变异毒株对经济增长的威胁较小，推动周四美元企稳、美股攀升推动道指与标普500指数再创盘中新高。</p><p>6、年末美国失业救济数据发布 黄金上涨美债下跌</p><p>美国上周首次申请失业救济人数意外下降，表明尽管爆发新一轮疫情，但劳动力需求仍然强劲。</p><p>美国劳工部周四的数据显示，在截至12月25日的一周，首次申领失业救济人数总计为198，000人，较前一周期的修正水平下降8，000人。接受调查的经济学家预估中值为206，000人。</p><p>国际宏观</p><p>1、<a href=\"https://laohu8.com/NW/2195497346\" target=\"_blank\">桥水创始人达利欧：美联储可能加息4-5次 明年这将是一个敏感问题</a></p><p>全球最大对冲基金桥水基金创始人瑞·达利欧在接受记者专访时表示，预计美联储明年将加息4-5次，直到对股市产生负面影响为止。</p><p>对于当前的通胀压力，达利欧指出，美国现在有两种通胀：一种是当对商品和服务的需求超过生产能力时出现的周期性通货膨胀，另一种是由货币和信贷超发造成的货币通胀。</p><p>对于第二种通胀，他警告，如果现金和债券持有人要大举抛售这些资产，央行将不得不以更快速度加息，或者通过印钞和购买金融资产来维持低利率，而这将加剧通货膨胀。这给美联储的政策制定增加了难度。</p><p>2、<a href=\"https://laohu8.com/NW/2195491270\" target=\"_blank\">美国CDC：无论接种疫苗与否，民众应避免邮轮旅行</a></p><p>美国疾病控制与预防中心（CDC）周四建议民众不要乘坐邮轮旅行，无论他们的疫苗接种情况如何，因奥密克戎变种席卷全球，近期新冠阳性病例大幅增加。</p><p>CDC将对邮轮的旅行警告提高到了最高级别。该机构目前正调查或观察数十艘爆发新冠疫情的邮轮。</p><p>CDC警告称，新冠病毒在船上近距离人与人之间很容易传播，即使接种了新冠疫苗和加强针，在邮轮上感染病毒的几率也非常高。</p><p>3、<a href=\"https://laohu8.com/NW/2195494014\" target=\"_blank\">美国取消航班再超千次，混乱的假日旅行季还在继续</a></p><p>由于冠状病毒病例激增导致人手严重不足，美国航空公司的航班取消数量还在增长，周四又有1，170个航班被取消。而预报中的暴风雪可能在新年假期进一步打乱人们的出行。</p><p>根据FlightAware.com，截至纽约时间周四下午2：27，捷蓝航空取消了175个航班，占其计划航班的17%。Allegiant取消了93个航班，占计划航班的18%。联合航空取消了197个，占计划的9%。在中午之前，当天取消的航班数量已经超过周三全天的1，084个。</p><p>此前，因冬季风暴加上人手不足，美国在圣诞节周末至本周初有数千航班取消。</p><p>4、美国上周首次申领失业救济人数意外下降 凸显劳动力需求仍强劲</p><p>美国上周首次申请失业救济人数意外下降，表明尽管爆发新一轮疫情，但劳动力需求仍然强劲。</p><p>美国劳工部周四的数据显示，在截至12月25日的一周，首次申领失业救济人数总计为198，000人，较前一周期的修正水平下降8，000人。接受彭博调查的经济学家预估中值为206，000人。</p><p>截至12月18日当周的持续申请失业救济人数下降至172万，为去年3月以来最低。</p><p>5、<a href=\"https://laohu8.com/NW/2195695494\" target=\"_blank\">全美公务员待遇“天花板”？美媒披露福奇每年退休金可得35万美元</a></p><p>报道称，已为美国政府效力55年的福奇连续两年成为“全美收入最高的公务员”：2019年的收入为41.7万美元，2020年涨到43.4万美元。他的薪资水平比美国总统、上将以及大约430万美国政府雇员都高。</p><p>根据美国联邦人事管理局的标准，福奇退休金的计算方法是其3年最高收入的平均值，再乘以80%。如果他在2021年和2022年获得的薪资与2020年持平，那么其退休金能达到34.7万美元。</p><p>另外，他的“超长工龄”能带来额外的政府年金补贴，数额至少是每年8344美元。</p><p>6、以色列正式批准开放第四剂新冠疫苗接种 限免疫力低下人群</p><p>当地时间12月30日晚间，以色列卫生部总干事纳赫曼·阿什（Nachman Ash）正式批准向该国免疫力低下人群开放第四剂新冠疫苗接种，但仍未批准向60岁以上人群以及医务工作者开放。</p><p>7、欧洲央行管委诺特：结束购债后可能会在2023年初加息</p><p>欧洲央行管委诺特称，欧洲央行接近实现2%的中期通胀目标，2022年通胀保持在2%上方的可能性很大，虽说不会远超2%。如果物价继续出人意料地上涨，央行可能会比现在计划的更快地解除刺激措施。政策利率可能在2023年初债券购买结束后上升。</p><p>8、欧洲央行管委维斯科：预计2022年平均通胀率为3%</p><p>欧洲央行管委维斯科称，预计2022年平均通胀率为3%，然后逐渐回落至略低于2%的水平；2023-24年的通胀预期预计将低于2%，面临下行和上行的风险。</p><p>公司新闻</p><p>1、<a href=\"https://laohu8.com/NW/2195911044\" target=\"_blank\">特斯拉在美国召回约47.5万辆汽车 接近其去年全球交付总量</a></p><p>由于技术缺陷可能增加事故风险，特斯拉召回美国约47.5万辆汽车，几乎相当于其去年全球总交付量。</p><p>特斯拉计划召回2017年至2020年间生产的所有Model 3车型，总数多达356，309辆。该公司告诉国家公路交通安全管理局(NHTSA)，后视摄像头的线束可能会因打开和关闭后备箱而受损，阻碍图像显示。</p><p>根据NHTSA周四在官网上发布的另一份声明，特斯拉还将召回2014年以来组装的多达119，009辆Model S汽车，因为前纵梁存在问题，可能导致引擎盖意外打开。该公司表示将免费解决这两个问题。</p><p>2、<a href=\"https://laohu8.com/NW/2195129491\" target=\"_blank\">缺芯危机中唯一的大赢家：特斯拉</a></p><p>全球汽车行业均受“缺芯”影响，然而特斯拉今年的产量预计将比去年多出大约80%。因为强大的自研芯片能力和垂直整合能力，特斯拉不惧“芯片荒”，成为行业最大赢家。</p><p>3、<a href=\"https://laohu8.com/NW/2195049505\" target=\"_blank\">2021年全球并购交易首次突破5万亿美元大关 高盛连续第五年力拔头筹</a></p><p>2021年全球并购交易创下纪录，高盛集团坐稳头把交椅。</p><p>根据彭博汇编的数据，根据所经手交易的美元总价值计算，高盛连续第五年蝉联合并与收购交易顾问榜首。</p><p>高盛占据首席之际，全球并购和相关交易规模首次超过了5万亿美元。数据显示，该行给价值超过1万亿美元的交易提供了咨询，市场占比超过24%。</p><p>4、<a href=\"https://laohu8.com/NW/2195496957\" target=\"_blank\">美国航空业面临疫情考验 捷蓝航空宣布将取消约1280架次航班</a></p><p>捷蓝航空表示，由于机组人员中感染奥密克戎毒株的病例大幅增加，该公司将1月13日之前的航班班次减少约1280次。</p><p>捷蓝航空发言人称，预计在未来一到两周内，该公司大多数机组人员所在的东北部地区的新冠肺炎病例数量将继续激增，这意味着，在新增病例数量下降之前，继续取消航班的可能性很高。</p><p>5、<a href=\"https://laohu8.com/NW/2195495066\" target=\"_blank\">三星否认收购不要紧 Canaccord Genuity预计百健下行空间有限</a></p><p>Canaccord Genuity分析师Sumant Kulkarni维持百健（BIIB.US）“买入”评级，目标价390美元。</p><p>此前，韩国媒体报道称，三星集团正在就收购百健进行谈判，并称估值约为420亿美元。随后，三星旗下三星生物表示这些是不真实的信息。</p><p>Kulkarni在一份报告中表示：“平心而论，这看起来确实像是一种断然否认。但是，我们缺乏相关语言背景，无法弄清韩语文件中具体被认定为不真实内容的细微差别。”</p><p>6、<a href=\"https://laohu8.com/NW/2195496771\" target=\"_blank\">员工抱怨亚马逊太冷酷：工伤后得不到赔偿，还不让休假</a></p><p>据报道，一些亚马逊员工日前抱怨，他们在工作中受伤后，很难获得赔偿和休假。</p><p>今年6月有分析称，亚马逊仓储员工在工作中的重伤率几乎是业内其他公司的两倍。该数据显示，2020年亚马逊仓储员工在每20万小时工作中，平均有5.9起“严重”受伤事件。</p><p>相比之下，整个仓储行业每20万小时平均发生“严重”受伤事件3.3起。作为亚马逊在零售行业最大的竞争对手之一，沃尔玛每20万小时发生2.5起“严重”受伤事件，不到亚马逊重伤率的一半。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157350742","content_text":"昨夜今晨：①美股尾盘跳水！道指跌0.25%止步六连阳；②周四美油收高0.3%，布油涨0.1%；③桥水创始人达利欧预计美联储明年可能加息4-5次；④欧洲央行管委诺特：结束购债后可能会在2023年初加息。海外市场1、美股尾盘跳水！道指跌0.25%止步六连阳美股三大指数高开低走，标普和纳指在周四交易时段的最后几分钟转跌，道琼斯指数也结束六连阳。截至收盘，道琼斯指数跌0.25%，标普500指数跌0.30%，纳斯达克指数跌0.16%。美股大型科技股表现不尽人意。按市值排序，苹果跌0.66%，微软跌0.77%，谷歌A跌0.34%，亚马逊跌0.33%，特斯拉跌1.46%，英伟达跌1.38%，仅Meta涨0.41%。通常情况下，美股会在一年的最后五个交易日和新年的前两个交易日上涨，这种现象被称为“圣诞行情”。低于平均水平的交易量，加上许多投资者在假期休市，可能导致交易波动扩大。一些公司还在年底调整投资组合。2、热门中概股周四收盘大涨 高途涨超21%热门中概股周四收盘大涨，高途、爱奇艺、哔哩哔哩等涨幅居前；纳斯达克金龙中国指数收涨9.40%，创2008年以来最大单日涨幅。高途涨超21%，爱奇艺、汽车之家涨超13%，哔哩哔哩、唯品会、贝壳涨超12%，阿里巴巴、趣头条涨超9%，网易涨近9%。新能源汽车股中，蔚来汽车涨超14%，小鹏汽车涨近10%，理想汽车涨超8%。3、欧股主要指数上涨 德国DAX30收涨0.34%德国DAX30指数周四收涨0.34%，英国富时100指数跌0.19%，法国CAC40指数涨0.16%，欧洲斯托克50指数涨0.50%。4、周四美油收高0.6% 逼近每桶77美元美国原油期货价格周四收高。市场对于奥密克戎变异毒株阻碍经济复苏的担忧情绪缓解、迹象表明原油库存下降，令油价得到支撑。周四，纽约商品交易所2月交割的西德州中质原油期货价格上涨43美分，涨幅0.6%，收于每桶76.99美元。伦敦洲际交易所2月交割的布伦特原油期货价格上涨9美分，涨幅0.1%，收于每桶79.32美元。至此布伦特原油期货已经连续四个交易日上涨。5、周四黄金期货收高0.5%尽管美元企稳、美股走高，黄金期货价格周四仍然收涨。投资者认为奥密克戎变异毒株对经济增长的威胁较小，推动周四美元企稳、美股攀升推动道指与标普500指数再创盘中新高。6、年末美国失业救济数据发布 黄金上涨美债下跌美国上周首次申请失业救济人数意外下降，表明尽管爆发新一轮疫情，但劳动力需求仍然强劲。美国劳工部周四的数据显示，在截至12月25日的一周，首次申领失业救济人数总计为198，000人，较前一周期的修正水平下降8，000人。接受调查的经济学家预估中值为206，000人。国际宏观1、桥水创始人达利欧：美联储可能加息4-5次 明年这将是一个敏感问题全球最大对冲基金桥水基金创始人瑞·达利欧在接受记者专访时表示，预计美联储明年将加息4-5次，直到对股市产生负面影响为止。对于当前的通胀压力，达利欧指出，美国现在有两种通胀：一种是当对商品和服务的需求超过生产能力时出现的周期性通货膨胀，另一种是由货币和信贷超发造成的货币通胀。对于第二种通胀，他警告，如果现金和债券持有人要大举抛售这些资产，央行将不得不以更快速度加息，或者通过印钞和购买金融资产来维持低利率，而这将加剧通货膨胀。这给美联储的政策制定增加了难度。2、美国CDC：无论接种疫苗与否，民众应避免邮轮旅行美国疾病控制与预防中心（CDC）周四建议民众不要乘坐邮轮旅行，无论他们的疫苗接种情况如何，因奥密克戎变种席卷全球，近期新冠阳性病例大幅增加。CDC将对邮轮的旅行警告提高到了最高级别。该机构目前正调查或观察数十艘爆发新冠疫情的邮轮。CDC警告称，新冠病毒在船上近距离人与人之间很容易传播，即使接种了新冠疫苗和加强针，在邮轮上感染病毒的几率也非常高。3、美国取消航班再超千次，混乱的假日旅行季还在继续由于冠状病毒病例激增导致人手严重不足，美国航空公司的航班取消数量还在增长，周四又有1，170个航班被取消。而预报中的暴风雪可能在新年假期进一步打乱人们的出行。根据FlightAware.com，截至纽约时间周四下午2：27，捷蓝航空取消了175个航班，占其计划航班的17%。Allegiant取消了93个航班，占计划航班的18%。联合航空取消了197个，占计划的9%。在中午之前，当天取消的航班数量已经超过周三全天的1，084个。此前，因冬季风暴加上人手不足，美国在圣诞节周末至本周初有数千航班取消。4、美国上周首次申领失业救济人数意外下降 凸显劳动力需求仍强劲美国上周首次申请失业救济人数意外下降，表明尽管爆发新一轮疫情，但劳动力需求仍然强劲。美国劳工部周四的数据显示，在截至12月25日的一周，首次申领失业救济人数总计为198，000人，较前一周期的修正水平下降8，000人。接受彭博调查的经济学家预估中值为206，000人。截至12月18日当周的持续申请失业救济人数下降至172万，为去年3月以来最低。5、全美公务员待遇“天花板”？美媒披露福奇每年退休金可得35万美元报道称，已为美国政府效力55年的福奇连续两年成为“全美收入最高的公务员”：2019年的收入为41.7万美元，2020年涨到43.4万美元。他的薪资水平比美国总统、上将以及大约430万美国政府雇员都高。根据美国联邦人事管理局的标准，福奇退休金的计算方法是其3年最高收入的平均值，再乘以80%。如果他在2021年和2022年获得的薪资与2020年持平，那么其退休金能达到34.7万美元。另外，他的“超长工龄”能带来额外的政府年金补贴，数额至少是每年8344美元。6、以色列正式批准开放第四剂新冠疫苗接种 限免疫力低下人群当地时间12月30日晚间，以色列卫生部总干事纳赫曼·阿什（Nachman Ash）正式批准向该国免疫力低下人群开放第四剂新冠疫苗接种，但仍未批准向60岁以上人群以及医务工作者开放。7、欧洲央行管委诺特：结束购债后可能会在2023年初加息欧洲央行管委诺特称，欧洲央行接近实现2%的中期通胀目标，2022年通胀保持在2%上方的可能性很大，虽说不会远超2%。如果物价继续出人意料地上涨，央行可能会比现在计划的更快地解除刺激措施。政策利率可能在2023年初债券购买结束后上升。8、欧洲央行管委维斯科：预计2022年平均通胀率为3%欧洲央行管委维斯科称，预计2022年平均通胀率为3%，然后逐渐回落至略低于2%的水平；2023-24年的通胀预期预计将低于2%，面临下行和上行的风险。公司新闻1、特斯拉在美国召回约47.5万辆汽车 接近其去年全球交付总量由于技术缺陷可能增加事故风险，特斯拉召回美国约47.5万辆汽车，几乎相当于其去年全球总交付量。特斯拉计划召回2017年至2020年间生产的所有Model 3车型，总数多达356，309辆。该公司告诉国家公路交通安全管理局(NHTSA)，后视摄像头的线束可能会因打开和关闭后备箱而受损，阻碍图像显示。根据NHTSA周四在官网上发布的另一份声明，特斯拉还将召回2014年以来组装的多达119，009辆Model S汽车，因为前纵梁存在问题，可能导致引擎盖意外打开。该公司表示将免费解决这两个问题。2、缺芯危机中唯一的大赢家：特斯拉全球汽车行业均受“缺芯”影响，然而特斯拉今年的产量预计将比去年多出大约80%。因为强大的自研芯片能力和垂直整合能力，特斯拉不惧“芯片荒”，成为行业最大赢家。3、2021年全球并购交易首次突破5万亿美元大关 高盛连续第五年力拔头筹2021年全球并购交易创下纪录，高盛集团坐稳头把交椅。根据彭博汇编的数据，根据所经手交易的美元总价值计算，高盛连续第五年蝉联合并与收购交易顾问榜首。高盛占据首席之际，全球并购和相关交易规模首次超过了5万亿美元。数据显示，该行给价值超过1万亿美元的交易提供了咨询，市场占比超过24%。4、美国航空业面临疫情考验 捷蓝航空宣布将取消约1280架次航班捷蓝航空表示，由于机组人员中感染奥密克戎毒株的病例大幅增加，该公司将1月13日之前的航班班次减少约1280次。捷蓝航空发言人称，预计在未来一到两周内，该公司大多数机组人员所在的东北部地区的新冠肺炎病例数量将继续激增，这意味着，在新增病例数量下降之前，继续取消航班的可能性很高。5、三星否认收购不要紧 Canaccord Genuity预计百健下行空间有限Canaccord Genuity分析师Sumant Kulkarni维持百健（BIIB.US）“买入”评级，目标价390美元。此前，韩国媒体报道称，三星集团正在就收购百健进行谈判，并称估值约为420亿美元。随后，三星旗下三星生物表示这些是不真实的信息。Kulkarni在一份报告中表示：“平心而论，这看起来确实像是一种断然否认。但是，我们缺乏相关语言背景，无法弄清韩语文件中具体被认定为不真实内容的细微差别。”6、员工抱怨亚马逊太冷酷：工伤后得不到赔偿，还不让休假据报道，一些亚马逊员工日前抱怨，他们在工作中受伤后，很难获得赔偿和休假。今年6月有分析称，亚马逊仓储员工在工作中的重伤率几乎是业内其他公司的两倍。该数据显示，2020年亚马逊仓储员工在每20万小时工作中，平均有5.9起“严重”受伤事件。相比之下，整个仓储行业每20万小时平均发生“严重”受伤事件3.3起。作为亚马逊在零售行业最大的竞争对手之一，沃尔玛每20万小时发生2.5起“严重”受伤事件，不到亚马逊重伤率的一半。","news_type":1,"symbols_score_info":{".DJI":0,".IXIC":0,".SPX":0}},"isVote":1,"tweetType":1,"viewCount":2299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692831399,"gmtCreate":1640911331718,"gmtModify":1640911331797,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[财迷]&nbsp;[鼓掌]&nbsp;","listText":"[财迷]&nbsp;[鼓掌]&nbsp;","text":"[财迷] [鼓掌]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692831399","repostId":"2195944694","repostType":2,"isVote":1,"tweetType":1,"viewCount":2800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692808650,"gmtCreate":1640905456517,"gmtModify":1640905456632,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[开心]&nbsp;[强]&nbsp;[鼓掌]&nbsp;","listText":"[开心]&nbsp;[强]&nbsp;[鼓掌]&nbsp;","text":"[开心] [强] [鼓掌]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692808650","repostId":"2195494076","repostType":2,"isVote":1,"tweetType":1,"viewCount":2074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692184152,"gmtCreate":1640875937328,"gmtModify":1640875937429,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[捂脸]&nbsp;[喷血]&nbsp;","listText":"[捂脸]&nbsp;[喷血]&nbsp;","text":"[捂脸] [喷血]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692184152","repostId":"1176544303","repostType":4,"repost":{"id":"1176544303","kind":"news","pubTimestamp":1640866163,"share":"https://www.laohu8.com/m/news/1176544303?lang=&edition=full","pubTime":"2021-12-30 20:09","market":"us","language":"zh","title":"传特斯拉等新能源汽车保费涨超50%，车险公司回应：不实","url":"https://stock-news.laohu8.com/highlight/detail?id=1176544303","media":"第一财经","summary":"新能源汽车商业保险专属产品正式上线，在车主群体和舆论中引起了轩然大波。","content":"<div>\n<p>作者：魏文  杨倩雯新能源汽车商业保险专属产品正式上线，在车主群体和舆论中引起了轩然大波。有车主在社交媒体上爆料称，12月23日，他的Model Y投保的总费用为8278元而到了12月27日，同一辆车投保总费用就涨到14902元，涨幅高达80%。其中，车损险的涨幅最大，由此前的5759元涨到12736元。蔚来、小鹏等车企的产品也被爆出保费大幅上升的情况。但一家造车新势力经销商告诉记者，以其店内交付...</p>\n\n<a href=\"https://www.yicai.com/news/101275252.html\">Web Link</a>\n\n</div>\n","source":"dyvj","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传特斯拉等新能源汽车保费涨超50%，车险公司回应：不实</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传特斯拉等新能源汽车保费涨超50%，车险公司回应：不实\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 20:09 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.yicai.com/news/101275252.html><strong>第一财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>作者：魏文  杨倩雯新能源汽车商业保险专属产品正式上线，在车主群体和舆论中引起了轩然大波。有车主在社交媒体上爆料称，12月23日，他的Model Y投保的总费用为8278元而到了12月27日，同一辆车投保总费用就涨到14902元，涨幅高达80%。其中，车损险的涨幅最大，由此前的5759元涨到12736元。蔚来、小鹏等车企的产品也被爆出保费大幅上升的情况。但一家造车新势力经销商告诉记者，以其店内交付...</p>\n\n<a href=\"https://www.yicai.com/news/101275252.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1da1808c476bfbe9388a4202f176a117","relate_stocks":{},"source_url":"https://www.yicai.com/news/101275252.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176544303","content_text":"作者：魏文  杨倩雯新能源汽车商业保险专属产品正式上线，在车主群体和舆论中引起了轩然大波。有车主在社交媒体上爆料称，12月23日，他的Model Y投保的总费用为8278元而到了12月27日，同一辆车投保总费用就涨到14902元，涨幅高达80%。其中，车损险的涨幅最大，由此前的5759元涨到12736元。蔚来、小鹏等车企的产品也被爆出保费大幅上升的情况。但一家造车新势力经销商告诉记者，以其店内交付和保险公司沟通的情况来看，在新能源汽车专属保险上线之后，保费的确出现了上涨的情况，但没有网络上公布的那么夸张，他们测算在新能源专属保险上线之后，新车保险差价在500-1000元之间，涨幅在10%左右。以25万元左右的小鹏P7为例，小鹏汽车门店销售告诉记者，原本商业险是5000多元，现在6000元出头，上涨了大概15%-18%，具体要根据车主的交通违章情况，和之前的出险情况挂钩。某车险公司的销售则表示，之前新能源车保费中有10-15%的返利，现在的价格就相当于返利没有了，他12月29日录入的特斯拉MODEL Y价格上浮在10%左右，但同日比亚迪宋PLUS DM-i出现10%左右的下调。12月29日晚间，小鹏汽车发布了《关于新能源车险产品上线对于小鹏品牌车型商业车险的保费变化的说明》，小鹏汽车方面表示，“据28日各保司反馈的全国保费情况，小鹏全线车型平均涨幅2.9%~18.2%不等(不同保司、不同地区、不同车型涨幅略有差异），具体金额请以当地保司的报价为准。”蔚来汽车一位服务运营负责人告诉记者：“我们在看到网传的信息之后，也找我们合作的保险公司去征询了意见，根据各个保险公司的反馈，网图的信息是不准确的，当然他们每家给我们的反馈的绝对数值有高有低，但肯定是没有网传的这么离谱的。”他表示，从蔚来汽车目前的监测来看，保费有涨跌的，有部分车型可能还会比原来的保费更低的，但也有的车型是高了。蔚来目前监测下来是振幅不大的，大概是 10% 以内。12月29日晚间，蔚来召开新能源汽车专属保险沟通会，会上蔚来汽车表示，该公司向用户提供的包含保费及相关服务权益的2021版用户无忧保包，在车险费改之后，服务包价格依旧保持不变。不包含保险费用的保险无忧包，费用则会根据保司定价进行相应的调整。“这（涨价80%）肯定是夸张了，即使真有这个涨幅，也并不代表行业整体情况。”一名大型产险公司车险人士也对第一财经记者表示。据他介绍，新能源专属车险产品和之前相比保费有涨有跌，部分车型确实出现了涨价，但车险定价中需要考虑多种因素，即使是各新能源品牌同车价的保费变化也会有所不同。此前中国保险行业协会近日向财险公司下发的《关于新能源汽车商业保险专属产品基准纯风险保费表测算调整说明》显示，在车损险费率平滑方面，25万元以下车价的新能源汽车，基准保费一律不上浮；25万元以上车价的新能源汽车，基准保费可以上下浮动。而从商车改革后车险的定价规律来看，最终的定价在基准保费之上还将考虑一系列的费率调整系数，例如以前年度的出险次数就以无赔优待系数(NCD系数)的形式与车险最终定价密切相关，之前多次出险会呈现保费上涨，而连续三年未出险则会享受较低的车险保费折扣。另外，不同的新能源车品牌由于工艺技术大相径庭，其理赔成本也会有很大差异。一名车险理赔人士对记者表示，由于没有发动机，因此电池以及大灯、门、保险杠等表面覆盖件的维修成本是决定不同新能源车型的理赔成本的重要因素，一些造车新势力由于其零部件缺乏可替代性，因此其表面覆盖件维修成本较高，而一些传统车企推出的新能源版本其表面覆盖件可能会有通用性或副厂件等，维修成本大大下降；同时，部分新能源车的设计会导致在驾驶习惯方面的改变，往往使得部分司机在刚开始驾驶新能源车的时候比较难以掌控，也会导致赔付率的上升。针对一些过往赔付率较高的车型，险企也会通过自主定价系数来提高保费，以避免大幅承保亏损。因此，不同品牌车型和不同的驾驶表现会产生出截然不同的最终车险保费情况，一辆车的保费变化情况显然很难代表普遍情况。同时，也有险企人士表示，和过去使用传统商业车险条款相比，新能源汽车商业保险专属产品扩大了新能源车型保障范围，新能源车险核心部分的“三电”系统（电池及储能系统、电机及驱动系统、其他控制系统）均纳入承保范围，车辆行驶、停放、充电及作业期间的车损也被纳入承保范围；并新增了三条新能源车特有附加险：附加外部电网故障损失险、附加自用充电桩损失险和附加自用充电桩责任险。而保障范围的不同也使得两个条款下的车险保费可比性下降。究其根本，新能源车的部分车型面临保费上涨主要就是因为险企赔付率过高。申万宏源报告数据显示，目前新能源车险的赔付率平均接近 85%，行业面临较大承保亏损压力。业内人士表示，新能源车作为一个新生事物，其数据积累和承保经验相对燃油车来说还是欠缺的，而随着之后新能源车的技术发展、险企承保数据的积累以及定价和风控的进一步精细化，赔付率也将回归至合理水平。同时，此次新能源车险专属条款括号里的“试行”两字也给今后的变化留下了空间。华安保险表示，随着新能源汽车技术的快速迭代，新能源车险条款也会不断完善，未来条款的修订或将常态化。","news_type":1,"symbols_score_info":{"09868":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692182208,"gmtCreate":1640875594149,"gmtModify":1640875594225,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[惊讶]&nbsp;","listText":"[惊讶]&nbsp;","text":"[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692182208","repostId":"2194099433","repostType":2,"isVote":1,"tweetType":1,"viewCount":1868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692181972,"gmtCreate":1640875041851,"gmtModify":1640875065565,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692181972","repostId":"2191000948","repostType":2,"isVote":1,"tweetType":1,"viewCount":2753,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692183759,"gmtCreate":1640875020800,"gmtModify":1640875020936,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[汗颜]&nbsp;","listText":"[汗颜]&nbsp;","text":"[汗颜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692183759","repostId":"2194988102","repostType":2,"isVote":1,"tweetType":1,"viewCount":2440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692183502,"gmtCreate":1640874976480,"gmtModify":1640874976588,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692183502","repostId":"1105609028","repostType":2,"repost":{"id":"1105609028","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640586449,"share":"https://www.laohu8.com/m/news/1105609028?lang=&edition=full","pubTime":"2021-12-27 14:27","market":"us","language":"en","title":"The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1105609028","media":"Benzinga","summary":"Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinic","content":"<p>Biopharma stocks eked out modest gains in the week ending&nbsp;Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments&nbsp;dictating sentiment.</p>\n<p>The week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills.&nbsp;<b>Pfizer, Inc.</b>received authorization for its oral drug Paxlovid on Wednesday, followed by&nbsp;<b>Merck &amp; Co., Inc.'s</b>&nbsp;molnupiravir.</p>\n<p><b>BiondVax Pharmaceuticals Ltd.</b>rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.</p>\n<p><b>Allakos Inc.</b>&nbsp;was among the worst performers of the week after the company's investigational compound&nbsp;flunkedlate-stage studies in inflammation of the digestive tract.</p>\n<p>Here are the key biopharma catalysts for the unfolding week:</p>\n<p><b>PDUFA Dates</b></p>\n<p>The FDA is scheduled to announce its verdict on&nbsp;<b>Xeris Biopharma Holdings, Inc.'s</b>&nbsp;new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.</p>\n<p>Clinical Readouts/Presentations</p>\n<p><b>Year-end Releases</b></p>\n<p><b>Anavex Life Sciences Corp.</b>: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans</p>\n<p><b>Vanda Pharmaceuticals Inc.</b>: results of Phase 3 study off tradipitant in gastroparesis</p>\n<p><b>Second-Half Data Releases</b></p>\n<p><b>Adagene Inc.</b>: Results from ongoing dose escalation of ADG126 monotherapy in solid tumors</p>\n<p><b>Fourth-quarter Releases</b></p>\n<p><b>Corbus Pharmaceuticals Holdings, Inc.</b>: topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus</p>\n<p><b>Vir Biotechnology, Inc.</b>: initial VIR-111, its HIV vaccine candidate, immunology data</p>\n<p><b>Avalo Therapeutics, Inc.</b>: opline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected</p>\n<p><b>December Releases</b></p>\n<p><b>Taysha Gene Therapies, Inc.</b>: clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in giant axonal neuropathy and preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis</p>\n<p><b>2021/Late-2021 Releases</b></p>\n<p><b>BridgeBio Pharma, Inc.</b>: topline results from Part A of the Phase 3 ATTRibute-CM trial of Acoramidis for transthyretin amyloid cardiomyopathy (late-2021)</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-27 14:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biopharma stocks eked out modest gains in the week ending&nbsp;Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments&nbsp;dictating sentiment.</p>\n<p>The week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills.&nbsp;<b>Pfizer, Inc.</b>received authorization for its oral drug Paxlovid on Wednesday, followed by&nbsp;<b>Merck &amp; Co., Inc.'s</b>&nbsp;molnupiravir.</p>\n<p><b>BiondVax Pharmaceuticals Ltd.</b>rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.</p>\n<p><b>Allakos Inc.</b>&nbsp;was among the worst performers of the week after the company's investigational compound&nbsp;flunkedlate-stage studies in inflammation of the digestive tract.</p>\n<p>Here are the key biopharma catalysts for the unfolding week:</p>\n<p><b>PDUFA Dates</b></p>\n<p>The FDA is scheduled to announce its verdict on&nbsp;<b>Xeris Biopharma Holdings, Inc.'s</b>&nbsp;new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.</p>\n<p>Clinical Readouts/Presentations</p>\n<p><b>Year-end Releases</b></p>\n<p><b>Anavex Life Sciences Corp.</b>: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans</p>\n<p><b>Vanda Pharmaceuticals Inc.</b>: results of Phase 3 study off tradipitant in gastroparesis</p>\n<p><b>Second-Half Data Releases</b></p>\n<p><b>Adagene Inc.</b>: Results from ongoing dose escalation of ADG126 monotherapy in solid tumors</p>\n<p><b>Fourth-quarter Releases</b></p>\n<p><b>Corbus Pharmaceuticals Holdings, Inc.</b>: topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus</p>\n<p><b>Vir Biotechnology, Inc.</b>: initial VIR-111, its HIV vaccine candidate, immunology data</p>\n<p><b>Avalo Therapeutics, Inc.</b>: opline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected</p>\n<p><b>December Releases</b></p>\n<p><b>Taysha Gene Therapies, Inc.</b>: clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in giant axonal neuropathy and preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis</p>\n<p><b>2021/Late-2021 Releases</b></p>\n<p><b>BridgeBio Pharma, Inc.</b>: topline results from Part A of the Phase 3 ATTRibute-CM trial of Acoramidis for transthyretin amyloid cardiomyopathy (late-2021)</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105609028","content_text":"Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.\nThe week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. Pfizer, Inc.received authorization for its oral drug Paxlovid on Wednesday, followed by Merck & Co., Inc.'s molnupiravir.\nBiondVax Pharmaceuticals Ltd.rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.\nAllakos Inc. was among the worst performers of the week after the company's investigational compound flunkedlate-stage studies in inflammation of the digestive tract.\nHere are the key biopharma catalysts for the unfolding week:\nPDUFA Dates\nThe FDA is scheduled to announce its verdict on Xeris Biopharma Holdings, Inc.'s new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.\nClinical Readouts/Presentations\nYear-end Releases\nAnavex Life Sciences Corp.: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans\nVanda Pharmaceuticals Inc.: results of Phase 3 study off tradipitant in gastroparesis\nSecond-Half Data Releases\nAdagene Inc.: Results from ongoing dose escalation of ADG126 monotherapy in solid tumors\nFourth-quarter Releases\nCorbus Pharmaceuticals Holdings, Inc.: topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus\nVir Biotechnology, Inc.: initial VIR-111, its HIV vaccine candidate, immunology data\nAvalo Therapeutics, Inc.: opline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected\nDecember Releases\nTaysha Gene Therapies, Inc.: clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in giant axonal neuropathy and preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis\n2021/Late-2021 Releases\nBridgeBio Pharma, Inc.: topline results from Part A of the Phase 3 ATTRibute-CM trial of Acoramidis for transthyretin amyloid cardiomyopathy (late-2021)","news_type":1,"symbols_score_info":{"ADAG":0.9,"AVTX":0.9,"AVXL":0.9,"BBIO":0.9,"CRBP":0.9,"TSHA":0.9,"VIR":0.9,"VNDA":0.9,"XERS":0.9}},"isVote":1,"tweetType":1,"viewCount":2001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692180067,"gmtCreate":1640874588610,"gmtModify":1640874588687,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[冷漠]&nbsp;","listText":"[冷漠]&nbsp;","text":"[冷漠]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692180067","repostId":"1114898675","repostType":2,"repost":{"id":"1114898675","kind":"news","pubTimestamp":1640745937,"share":"https://www.laohu8.com/m/news/1114898675?lang=&edition=full","pubTime":"2021-12-29 10:45","market":"us","language":"en","title":"ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1114898675","media":"InvestorPlace","summary":"The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:","content":"<p>The short-squeeze trade doesn’t appear to be over. Indeed, for investors in&nbsp;<b>Insignia Systems</b>(NASDAQ:<b><u>ISIG</u></b>) and&nbsp;ISIG stock, this trade appears to have some serious legs.</p>\n<p>Various micro cap stocks such as Insignia Systems are seeing impressive buying pressure today. Retail investors are smashing the bid on companies with higher-than-average short interest. As it happens, Insignia Systems is currently one of the most shorted stocks in the market. The company’s&nbsp;short interest ratio&nbsp;of 61% is very high, signaling this stock could be a prime candidate for a squeeze.</p>\n<p>Insignia’s business model is also intriguing to aggressive growth investors. This company focuses on providing physical and digital advertising solutions to clientele in the U.S. As the economy continues to recover from this pandemic, there’s a fundamental growth thesis for this company as well.</p>\n<p>That said, today, all eyes are on Insignia’s potential as a short-squeeze play. Let’s dive into some of the chatter that’s driving this company higher today.</p>\n<p>ISIG Stock Surges Amid Another Short-Squeeze Frenzy</p>\n<p>Any time a company sees roughly 10 times the average daily volume of shares traded before the afternoon, investors know something is up. In the case of Insignia, impressive retail-buying momentum appears to be the cause of this rally today.</p>\n<p>A number of social media sites have lit up with mentions of ISIG stock. Among the top sites capturing eyeballs today is&nbsp;<b>Reddit</b>, and the r/Shortsqueeze channel in particular.</p>\n<p>A number of users have posted their&nbsp;due diligence on the fundamentals&nbsp;that may support a squeeze. A low float, relatively low price per share, and high short interest ratio are among the key factors short-squeeze enthusiasts are jumping on today. Indeed, at a high level, Insignia certainly does appear to be an attractive short-squeeze candidate given these factors.</p>\n<p>That said, this stock has been a highly volatile one this month. Shares of ISIG stock opened the month around $5 per share. This stock then soared to more than $35 per share, before deflating toward the $10 level. Today’s rise of more than 60% has brought ISIG stock back near the $20 level.</p>\n<p>Accordingly, where this stock goes from here remains uncertain. Investors betting on a squeeze must also be aware of the downside risks with such a stock. These volatile moves may be around for some time, so sit back and grab your popcorn. This looks like a fun one to watch.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/isig-stock-alert-the-short-squeeze-chatter-sending-insignia-systems-soaring-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:ISIG) and ISIG stock, this trade appears to have some serious legs.\nVarious micro cap stocks such as...</p>\n\n<a href=\"https://investorplace.com/2021/12/isig-stock-alert-the-short-squeeze-chatter-sending-insignia-systems-soaring-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/isig-stock-alert-the-short-squeeze-chatter-sending-insignia-systems-soaring-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114898675","content_text":"The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:ISIG) and ISIG stock, this trade appears to have some serious legs.\nVarious micro cap stocks such as Insignia Systems are seeing impressive buying pressure today. Retail investors are smashing the bid on companies with higher-than-average short interest. As it happens, Insignia Systems is currently one of the most shorted stocks in the market. The company’s short interest ratio of 61% is very high, signaling this stock could be a prime candidate for a squeeze.\nInsignia’s business model is also intriguing to aggressive growth investors. This company focuses on providing physical and digital advertising solutions to clientele in the U.S. As the economy continues to recover from this pandemic, there’s a fundamental growth thesis for this company as well.\nThat said, today, all eyes are on Insignia’s potential as a short-squeeze play. Let’s dive into some of the chatter that’s driving this company higher today.\nISIG Stock Surges Amid Another Short-Squeeze Frenzy\nAny time a company sees roughly 10 times the average daily volume of shares traded before the afternoon, investors know something is up. In the case of Insignia, impressive retail-buying momentum appears to be the cause of this rally today.\nA number of social media sites have lit up with mentions of ISIG stock. Among the top sites capturing eyeballs today is Reddit, and the r/Shortsqueeze channel in particular.\nA number of users have posted their due diligence on the fundamentals that may support a squeeze. A low float, relatively low price per share, and high short interest ratio are among the key factors short-squeeze enthusiasts are jumping on today. Indeed, at a high level, Insignia certainly does appear to be an attractive short-squeeze candidate given these factors.\nThat said, this stock has been a highly volatile one this month. Shares of ISIG stock opened the month around $5 per share. This stock then soared to more than $35 per share, before deflating toward the $10 level. Today’s rise of more than 60% has brought ISIG stock back near the $20 level.\nAccordingly, where this stock goes from here remains uncertain. Investors betting on a squeeze must also be aware of the downside risks with such a stock. These volatile moves may be around for some time, so sit back and grab your popcorn. This looks like a fun one to watch.","news_type":1,"symbols_score_info":{"ISIG":0.9}},"isVote":1,"tweetType":1,"viewCount":1681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692910710,"gmtCreate":1640825754426,"gmtModify":1640825754545,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[笑哭]&nbsp;","listText":"[笑哭]&nbsp;","text":"[笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692910710","repostId":"1175206227","repostType":2,"isVote":1,"tweetType":1,"viewCount":1695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}